Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
RVPH

RVPH - Reviva Pharmaceuticals Holdings Stock Price, Fair Value and News

1.25USD-0.02 (-1.57%)Market Closed

Market Summary

RVPH
USD1.25-0.02
Market Closed
-1.57%

RVPH Stock Price

View Fullscreen

RVPH RSI Chart

RVPH Valuation

Market Cap

35.5M

Price/Earnings (Trailing)

-0.89

EV/EBITDA

-0.64

Price/Free Cashflow

-1.1

MarketCap/EBT

-0.89

RVPH Price/Earnings (Trailing)

RVPH Profitability

Return on Equity

3.0K%

Return on Assets

-295.21%

Free Cashflow Yield

-90.53%

RVPH Fundamentals

RVPH Earnings

Earnings (TTM)

-39.8M

Earnings Growth (Yr)

-8.49%

Earnings Growth (Qtr)

20.54%

Breaking Down RVPH Revenue

Last 7 days

18.7%

Last 30 days

-14.8%

Last 90 days

-65.6%

Trailing 12 Months

-74.1%

How does RVPH drawdown profile look like?

RVPH Financial Health

Current Ratio

0

RVPH Investor Care

Shares Dilution (1Y)

35.30%

Tracking the Latest Insider Buys and Sells of Reviva Pharmaceuticals Holdings

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 18, 2022
patel purav
bought
14,070
4.69
3,000
-
Sep 30, 2022
narayan prabhu
bought
83,000
1.66
50,000
chief financial officer
Jun 30, 2022
narayan prabhu
bought
60,670
1.2134
50,000
chief financial officer
Jun 01, 2021
vedanta partners, llc
bought
4,987,500
3.75
1,330,000
-
Dec 14, 2020
tenzing llc
acquired
-
-
197,500
-

1–5 of 5

Which funds bought or sold RVPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
EMC Capital Management
unchanged
-
-227,000
411,000
0.25%
May 20, 2024
Virtu Financial LLC
sold off
-100
-78,000
-
-%
May 16, 2024
Colony Group, LLC
added
41.32
23,000
646,000
-%
May 16, 2024
B. Riley Wealth Advisors, Inc.
new
-
17,096
17,096
-%
May 16, 2024
JANE STREET GROUP, LLC
added
3.43
-36,079
113,740
-%
May 15, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-195,921
-
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
sold off
-100
-9,084,600
-
-%
May 15, 2024
Man Group plc
sold off
-100
-253,359
-
-%
May 15, 2024
Schonfeld Strategic Advisors LLC
new
-
3,124,550
3,124,550
0.02%
May 15, 2024
Arena Investors LP
unchanged
-
-61,701,000
56,449,000
0.85%

1–10 of 37

Are Funds Buying or Selling RVPH?

Are funds buying RVPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RVPH
No. of Funds

Unveiling Reviva Pharmaceuticals Holdings's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 31, 2024
vedanta partners, llc
4%
1
SC 13D/A
Feb 16, 2024
bhat laxminarayan
10.2%
2,885,678
SC 13D/A
Feb 14, 2024
tang capital partners lp
9.99%
3,098,615
SC 13G/A
Feb 14, 2024
armistice capital, llc
6.32%
1,764,000
SC 13G
Nov 30, 2023
vedanta partners, llc
9.0%
2,656,918
SC 13D/A
May 05, 2023
bhat laxminarayan
13.5%
2,811,545
SC 13D/A
Feb 14, 2023
tang capital partners lp
9.99%
2,266,229
SC 13G/A
Sep 12, 2022
vedanta partners, llc
12.0%
2,656,918
SC 13D/A
Jan 19, 2021
tenzing llc
27.24%
2,662,250
SC 13D/A
Jan 19, 2021
tenzing llc
22.98%
2,121,750
SC 13D/A

Recent SEC filings of Reviva Pharmaceuticals Holdings

View All Filings
Date Filed Form Type Document
Jul 09, 2024
8-K
Current Report
May 31, 2024
SC 13D/A
13D - Major Acquisition
May 29, 2024
8-K
Current Report
May 29, 2024
424B5
Prospectus Filed
May 17, 2024
S-8
Employee Benefits Plan
May 15, 2024
8-K
Current Report
May 14, 2024
8-K
Current Report
May 14, 2024
10-Q
Quarterly Report
Apr 15, 2024
8-K
Current Report
Apr 15, 2024
8-K
Current Report

Peers (Alternatives to Reviva Pharmaceuticals Holdings)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-17.23% -2.46%
-7.8
6.8
-64.45% -224.75%
33.0B
2.0B
67.01% 29.40%
-99.43
16.48
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.9B
2.5B
0.02% -1.58%
77.55
6.45
13.74% 186.89%
14.0B
3.8B
4.74% -0.56%
18.76
3.71
8.58% 129.81%
MID-CAP
5.0B
107.9M
-2.22% 48.86%
-9.2
48.09
54.84% -28.31%
4.7B
524.1M
-9.01% -54.24%
-11.31
9.01
394.93% 39.61%
4.0B
251.0M
18.93% 13.89%
-13.55
16
73.58% -86.73%
3.5B
240.7M
14.65% -16.72%
-7.42
12.77
-1.03% -213.92%
2.9B
813.8M
17.43% -31.75%
-1.7K
3.58
56.43% 98.83%
1.8B
996.6M
-22.65% 38.54%
-4.61
1.85
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
4.82% 27.42%
30.04
4.76
60.38% -34.49%
628.3M
881.7K
6.14% 580.25%
-18.61
481.06
-77.61% 33.36%
293.1M
4.2M
13.80% 73.74%
-2.35
70.45
-66.30% 48.24%
21.0M
2.1M
-12.55% 263.94%
-0.91
7.61
-13.45% 69.54%

Reviva Pharmaceuticals Holdings News

Latest updates
Defense World35 hours ago
openPR01 Jul 202410:15 pm

Reviva Pharmaceuticals Holdings Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q42020Q32020Q22020Q12019Q42019Q42019Q3
Assets-43.1%13,49723,7005,38711,84212,90218,92424,04120,64325,26831,40433,89436,5356,6588,76234,69434,47834,45961,02263,74766,47366,270
  Current Assets---------------44.0038.00240139-150250
    Cash Equivalents-48.8%11,97423,3674,97211,15211,25618,52023,19219,42023,42129,68833,49235,8015,6448,76037.0016.0019869.00193*134211
Liabilities-17.5%14,84217,98218,19813,65711,28810,5296,4854,5833,9072,7181,6252,0142,1423,2975,0494,3753,8403,2636,8142,3142,248
  Current Liabilities-15.6%14,49217,17517,32412,64510,7329,9626,3794,4773,6232,3459741,1631,1011,333860736501300-10034.00
  Short Term Borrowings-332-223223668----------------
Shareholder's Equity-123.5%-1,3455,719-12,8101,6211,6148,39417,55616,06021,36128,68632,26934,5214,5165,4665,0005,0005,0005,000-5,0005,000
  Retained Earnings-5.5%-141,800-134,354-124,998-113,653-101,945-95,093-85,856-79,537-74,196-66,831-63,147-60,867-59,259-58,3101725201,0361,192-54,5261,3241,187
  Additional Paid-In Capital0.3%140,439140,070112,186111,836103,557103,486103,41095,59795,55795,51795,41595,38763,77563,775----18,645--
Shares Outstanding0%27,91927,91920,65022,65021,83420,44719,27018,46718,46714,43313,55510,961---------
Float-100.0%-103,700-----11,200---41,400--------59,058
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q42020Q32020Q32020Q22020Q22020Q12020Q1
Cashflow From Operations-32.1%-11,725-8,876-6,179-5,317-7,951-4,690-4,001-4,001-6,266-3,902-2,309-1,340-3,116-3,545--823--379-35.46-60.66-
  Share Based Compensation-5.5%3693913502,62152.0057.0041.0040.0040.0062.0028.0017.00---------
Cashflow From Investing----------------206--210-26,773-5,702
Cashflow From Financing-98.8%33227,272-5,21368719.007,774-70*98.00-31,497-38,695-27,793-27,219-26,608230-
  Buy Backs---------------109---26,984-6,269
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RVPH Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses  
Research and development$ 5,783,865$ 5,484,145
General and administrative2,138,2411,500,554
Total operating expenses7,922,1066,984,699
Loss from operations(7,922,106)(6,984,699)
Other income (expense)  
Gain on remeasurement of warrant liabilities456,17711,126
Interest expense(3,487)(7,655)
Interest income173,098147,011
Other expense(129,894)(14,494)
Total other income, net495,894135,988
Loss before provision for income taxes(7,426,212)(6,848,711)
Provision for income taxes7,3962,978
Net loss$ (7,433,608)$ (6,851,689)
Net loss per share:  
Basic and diluted (in dollars per share)$ (0.25)$ (0.31)
Weighted average shares outstanding  
Basic and diluted (in shares)29,887,32521,833,598

RVPH Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Assets [Abstract]  
Cash and cash equivalents$ 11,973,647$ 23,367,456
Prepaid clinical trial costs779,60278,295
Prepaid expenses and other current assets743,381254,637
Total Assets13,496,63023,700,388
Liabilities [Abstract]  
Short-term debt332,0000
Accounts payable5,720,4553,849,108
Accrued clinical expenses6,845,91011,966,812
Accrued compensation1,216,237958,607
Other accrued liabilities377,367400,490
Total current liabilities14,491,96917,175,017
Warrant liabilities350,478806,655
Total Liabilities14,842,44717,981,672
Commitments and Contingencies 
Stockholders' Equity (Deficit)  
Common stock, par value of $0.0001; 115,000,000 shares authorized; 27,918,560 issued and outstanding as of March 31, 2024 and December 31, 20232,7922,792
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2024 and December 31, 202300
Additional paid-in capital140,439,247140,070,172
Accumulated deficit(141,787,856)(134,354,248)
Total stockholders' equity (deficit)(1,345,817)5,718,716
Total Liabilities and Stockholders' Equity (Deficit)$ 13,496,630$ 23,700,388
RVPH
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
 CEO
 WEBSITEhttps://revivapharma.com
 INDUSTRYBiotechnology
 EMPLOYEES10

Reviva Pharmaceuticals Holdings Frequently Asked Questions


What is the ticker symbol for Reviva Pharmaceuticals Holdings? What does RVPH stand for in stocks?

RVPH is the stock ticker symbol of Reviva Pharmaceuticals Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Reviva Pharmaceuticals Holdings (RVPH)?

As of Thu Jul 11 2024, market cap of Reviva Pharmaceuticals Holdings is 35.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVPH stock?

You can check RVPH's fair value in chart for subscribers.

What is the fair value of RVPH stock?

You can check RVPH's fair value in chart for subscribers. The fair value of Reviva Pharmaceuticals Holdings is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Reviva Pharmaceuticals Holdings is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Reviva Pharmaceuticals Holdings a good stock to buy?

The fair value guage provides a quick view whether RVPH is over valued or under valued. Whether Reviva Pharmaceuticals Holdings is cheap or expensive depends on the assumptions which impact Reviva Pharmaceuticals Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVPH.